HOME >> BIOLOGY >> NEWS
Common treatment for methamphetamine overdose may damage brain cells

WASHINGTON, DC May 29, 2007 A common antipsychotic drug used in emergency rooms to treat methamphetamine overdose damages nerve cells in an area of the brain known to regulate movement, a new study shows.

The findings, derived from experiments with rats, indicate that only the combination of the medication, haloperidol, and methamphetamine causes the destructive effects, not either one alone. Senior author Bryan Yamamoto, PhD, and his team at Boston University School of Medicine suspect the damage results from the exaggerated stimulation of cells by the amino acid glutamate, which proves toxic to cells producing the neurotransmitter gamma-aminobutyric acid (GABA). Their results are published in the May 30 issue of The Journal of Neuroscience.

"This work in laboratory animals raises immediate concerns that a standard treatment for methamphetamine overdose in humans might worsen drug abuse-related brain injuries," says William Carlezon, PhD, at Harvard's McLean Hospital, who was not affiliated with the study. "A crucial next step is to determine how atypical antipsychotic medications would affect methamphetamine toxicity in the same model."

The rats in the experiment were injected with either methamphetamine or a saline solution over a period of eight hours. When the rats were given haloperidol before and nearly halfway through the eight-hour period, Yamamoto and his colleagues noted more than a fivefold rise in base levels of glutamate in the substantia nigra, a part of the brain known to play a role in movement disorders such as Huntington's disease.

After examining the long-term effects of the combination, they found that glutamate concentrations in the substantia nigra were twice as high in methamphetamine-treated rats as in saline-treated ones two days after injections. Yamamoto and his colleagues were able to link this rise in glutamate to the death of GABA-containing cells in one part of the substantia nigra.
'"/>

Contact: Sara Harris
sharris@sfn.org
202-962-4000
Society for Neuroscience
29-May-2007


Page: 1 2

Related biology news :

1. Common environmental chemicals in diet affect fetal ovarian development
2. Common cancer gene sends death order to tiny killer
3. Common genetic variation is linked to substantial risk for heart attack
4. Common fungicide causes long-term changes in mating behavior
5. DNA ends: Common tool, different job
6. Common gene version optimizes thinking -- but with a possible downside
7. Common mechanisms for viral DNA replication
8. Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia
9. Common cause of heart disease, diabetes may be treatable with malaria drug
10. Commonplace sugar compound silences seizures
11. Common garden plant threatened by climate change

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/9/2019)... ... July 08, 2019 , ... On June ... ownership of the innovation behind two Danisco amylase patent applications (EP2859097 and EP2825643). ... based on prior art was without merit and awarded costs to Danisco. ...
(Date:6/20/2019)... Fla. (PRWEB) , ... June 19, 2019 , ... ... recently announced by the Infectious Diseases Society of America Foundation, and the possibly ... on Aging to study infectious agents in AD, are a “welcome affirmation” of ...
(Date:6/14/2019)... ... ... Molecular diagnostics segment is the fastest-growing segment within the global IVD market. The ... are expected to drive the growth are infectious diseases, cancer, and transplant diagnostics. ... The World Molecular Diagnostics Market, 8th Edition . , The discovery of the structure ...
Breaking Biology News(10 mins):
(Date:7/17/2019)... PARK, Md. (PRWEB) , ... July 15, 2019 , ... ... DNA so that a certain trait can be removed, replaced, or edited, but Yiping ... is looking far beyond these traditional applications in his latest publication in Nature Plants. ...
(Date:7/17/2019)... (PRWEB) , ... July 16, ... ... a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene ... Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space ...
(Date:7/17/2019)... ... 2019 , ... Quidel is the market leader in point-of-care ... and Siemens Healthineers and Response Biomedical also are among the top companies. The ... (POC) Diagnostics . , Quidel is a market leader in rapid immunoassays and ...
(Date:7/11/2019)... ... ... At the most recent stem cell training course in Las Vegas ... Heroes Program. The Veterans included individuals and families from all over the US, with ... military Veteran, teacher or first responder to receive a regenerative therapy at a training ...
Breaking Biology Technology:
Cached News: